2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Non-Biological Therapies, Palliative Care, Biological Processes, Pathogenesis, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, MDS, MPN, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4420 Economic impact of replacing fragmented genomic evaluation with whole genome sequencing for comprehensive molecular characterization of myeloid malignancies

Niyati Shah, MPH, Mark G. Evans, MD2, Eric Duncavage, MD3, David H Spencer, MD, PhD4, Farah Abdulla, MD5, James Hamrick, MD, MPH6, Samuel Urrutia, MD, MS7
1 Caris Life Sciences, Phoenix, Arizona, United States
2 Caris Life Sciences, Phoenix, Arizona, United States
3 Washington University, St. Louis, Missouri, United States
4 Washington University, St. Louis, Missouri, United States
5 Caris Life Sciences, Phoenix, Arizona, United States
6 Caris Life Sciences, Phoenix, Arizona, United States
7 Washington University, St. Louis, Missouri, United States

Genomic evaluation of hematologic malignancies is critical for accurate diagnosis, risk stratification, and treatment selection. Current practice relies on fragmented testing across multiple platforms, which may increase provider burden and require additional workup when results are discordant, incomplete, or affected by technical failure. Whole-genome sequencing (WGS) enables broad detection of multiple alteration classes on a single platform and may be used in place of standard-of-care (SOC). A decision-analytic model was developed to compare SOC testing with a commercially available WGS assay in patients with suspected acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or myeloproliferative neoplasm (MPN) undergoing genomic evaluation.

SOC testing included conventional karyotyping, fluorescence in situ hybridization (FISH), and targeted next-generation sequencing. Limitations of SOC testing were captured in two downstream pathways: diagnostic ambiguity, defined as inconclusive or discordant results that did not support definitive disease classification, and karyotype failure. Diagnostic ambiguity rates were modeled as 15%, 21%, and 15% in AML, MDS and MPN, respectively (Gorak et al, Blood Adv, 2023). Patients were assumed to receive an additional disease-specific FISH panel and, in select cases (10%), a repeat biopsy (Engel-Nitz et al, BMC Clin Pathol, 2014). Karyotype failure rates were modeled as 13%, 16%, and 18% in AML, MDS and MPN respectively (Santos et al, Braz J Med Biol Res, 2019). Patients with karyotype failure entered one of four mutually exclusive pathways with rates for AML, MDS, MPN respectively: repeat karyotype with repeat biopsy (6%, 8%, 6%), repeat karyotype without a new biopsy (1%, 2%, 2%), chromosomal microarray analysis (<1%, 2%, 0%), or no additional testing (5%, 5%, 10%) informed by expert input and published estimates (Engel-Nitz et al; Levy et al, Blood Adv, 2023).

WGS replaced SOC testing components and associated limitations but not flow cytometry or polymerase chain reaction testing. WGS failure was 0% in the base case, consistent with successful sequencing of all samples in a prospective cohort (Duncavage EJ et al N Engl J Med, 2021). A scenario analysis assumed 2% WGS failure, with affected patients reverting to the SOC testing pathway. Test, pathology, and biopsy collection costs were based on the CY2026 Medicare Clinical Laboratory Fee Schedule, Outpatient Prospective Payment System, and Physician Fee Schedule (PFS) facility national averages. In a hospital-system scenario with in-house genomic evaluation capabilities, Barnes-Jewish Hospital was used as an illustrative academic hospital to estimate SOC resource costs by applying cost-to-charge ratios to gross charges from CMS price transparency files, consistent with AHRQ/CMS charge-to-cost methods (Pickens et al, AHRQ, 2021) and directionally aligned with assumptions in the Duncavage cost analysis.

Administrative burden was modeled as the cost of provider time associated with test ordering and risk-score calculation. Time per order was estimated at 4.56 minutes based on EHR event-log studies (Arndt et al, Ann Fam Med, 2017; Arndt et al, Ann Fam Med, 2024). Risk-score calculation time was assumed to be 7-10 minutes based on expert input and applied to SOC only. Provider time was monetized using a per-minute physician rate derived from Medicare PFS payment methodology, calculated with the applicable relative value unit, conversion factor, and physician work time.

Compared with SOC, WGS reduced the number of tests needed to complete genomic profiling by 2.33-2.42 per patient, resulting in savings of $1,064-$1,268, depending on myeloid malignancy type. A lower karyotype failure rate of 5% still resulted in savings of $868-$1,098. WGS generated additional administrative savings of $23-$28 per tested patient. In a scenario analysis incorporating WGS failure, total savings decreased by $86-$91 per tested patient. In a hospital-system scenario assuming in-house SOC testing, WGS was associated with total savings of $231-$477 per tested patient.

A consolidated genomic testing strategy for myeloid malignancies may reduce downstream testing and administrative burden, improving the diagnostic process for patients and providers. Estimated cost savings may vary by site of testing, billing rules, and reimbursement policies. Future work should assess the economic impact of risk stratification and treatment selection with a WGS assay.
Samuel Urrutia, MD, MS: Primum - Honoraria; Ascentage - Honoraria; Geron - Honoraria; Caris Life Sciences - Honoraria; Bristol-Myers Squibb - Research Funding; BMS - Research Funding; GSK - Research Funding; GSK - Research Funding; Primum - Consultancy (Includes expert testimony); Ascentage - Consultancy (Includes expert testimony); Geron - Consultancy (Includes expert testimony); Caris Life Sciences - Consultancy (Includes expert testimony); Caris Life Sciences - Consultancy (Includes expert testimony); Geron - Consultancy (Includes expert testimony)